Phase 1 Interstitial Lung Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 40 years or older.
- People who have been diagnosed with IPF (idiopathic pulmonary fibrosis) according to specific international guidelines from 2018.
- People whose lungs are still able to hold and move at least 40% of the expected amount of air for someone their age and size (based on a breathing test called FVC, taken within the last 3 months).
- People whose lungs are still able to transfer at least 30% of the expected amount of oxygen into the blood (based on a test called DLco, taken within the last 3 months).
- People who are currently taking nintedanib or pirfenidone for IPF, as long as the dose has been stable for at least 6 weeks before the screening visit.
- People who are able to use highly reliable birth control (99% or more effective) throughout the study and for 60 days after the last dose of the study drug — this applies to women who could become pregnant and to men whose partners could become pregnant.
- People who agree not to donate eggs or sperm during the study and for 60 days after the last dose of the study drug.
- People who are able to read and sign a consent form agreeing to take part.
Who may not be able to join:
- People who are currently taking an unapproved treatment for IPF-related scarring, or who are already participating in another clinical trial.
- People who have signs of an active infection (such as bronchitis, pneumonia, or a sinus infection) that could affect breathing test results during screening.
- People who have had a sudden worsening of their IPF in the 3 months before screening, or where the trial doctor suspects this may have occurred.
- People whose lung scans show that the extent of air sac damage (emphysema) is greater than the extent of scarring (fibrosis), as assessed by the trial doctor.
- People who have a significant medical condition — such as heart, liver, or kidney disease, or a recent cancer — that the trial doctor considers would make participation unsuitable.
- People whose liver function blood test results are above certain limits set by the trial (confirm with trial site for exact values).
- People whose haemoglobin (a measure of red blood cells) is below 10.0 g/dL.
- People who are pregnant or breastfeeding.
- People who are expected to receive a lung transplant during the study period (being on a transplant waiting list is acceptable).
- People who are currently taking, and expected to continue taking, any of the following medications during the study: amodiaquine, efavirenz, nevirapine, or ritonavir.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Joshua Mooney, MD, Stanford University
Phone: (650) 736-2246
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of participants who experience treatment-related adverse events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.